Literature DB >> 6336679

Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay.

S G Carruthers, D J Freeman, J C Koegler, W Howson, P A Keown, A Laupacis, C R Stiller.   

Abstract

We describe a simplified isocratic "high-performance" liquid-chromatographic method for measuring a new immunosuppressive drug, cyclosporin A, in biological fluids with use of its analogs cyclosporin C and cyclosporin D as internal standards. The method is reproducible and accurate and appears to be specific for cyclosporin A; the detection limit is 31 micrograms/L. The chromatographic measurements of the concentration of cyclosporin A in serum of patients receiving the drug were invariably lower than those by radioimmunoassay and the difference became more pronounced the greater the period of time after dosing. Because measurements of cyclosporin A in serum standards were almost identical with both techniques, the differences between the two sets of results for patients' samples suggests that the radioimmunoassay is nonspecific and measures metabolites of cyclosporin A.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336679

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  19 in total

1.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

2.  Blood cyclosporin concentrations and renal allograft dysfunction.

Authors:  D W Holt; J T Marsden; A Johnston; M Bewick; D H Taube
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-25

3.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

4.  Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.

Authors:  B Legg; M Rowland
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

5.  The effects of co-dergocrine on cyclosporin A pharmacokinetics and pharmacodynamics.

Authors:  D A Heinrichs; R Martell; C R Stiller; D Freeman; G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

6.  Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients.

Authors:  S K Gupta; B Legg; L R Solomon; R W Johnson; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

7.  Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients.

Authors:  P Bertault-Pérès; D Maraninchi; Y Carcassonne; J P Cano; J Barbet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Cyclosporine trough concentration monitoring in liver transplant patients.

Authors:  G J Burckart; R J Ptachcinski; R Venkataramanan; S Iwatsuki; C Esquivel; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

9.  Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatography.

Authors:  G J Burckart; R Venkataramanan; R J Ptachcinski; T E Starzl; B P Griffith; T R Hakala; J T Rosenthal; R L Hardesty; S Iwatsuki; J Brady
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

10.  The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig.

Authors:  D J Freeman; D R Grant; S G Carruthers
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.